Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Martin M. Fabani is active.

Publication


Featured researches published by Martin M. Fabani.


Nature Cell Biology | 2010

miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator

Dimitrios Lagos; Gabriel Pollara; Stephen Henderson; Fiona Gratrix; Martin M. Fabani; Richard S. B. Milne; Frances Gotch; Chris Boshoff

MicroRNAs are small, non-coding RNAs that negatively regulate gene expression. It has been proposed that microRNAs could function in the regulation of innate immunity, but this has not been demonstrated for viral infection. Here we test this hypothesis using the human pathogenic virus Kaposis sarcoma-associated herpesvirus (KSHV) and one of its putative natural cellular targets, primary lymphatic endothelial cells (LECs). We show that an early antiviral microRNA response (6 h post-infection) includes expression of microRNAs that enhance viral gene expression. In particular, the CREB-induced miR-132 microRNA is highly upregulated after infection and has a negative effect on the expression of interferon-stimulated genes, facilitating viral replication. We show a similar function for miR-132 during infection of monocytes with herpes simplex virus-1 (HSV-1) and human cytomegalovirus (HCMV). miR-132 regulates innate antiviral immunity by inhibiting expression of the p300 transcriptional co-activator. p300 is downregulated early after KSHV infection, and inhibition of miR-132 induction restores p300 expression. Furthermore, p300 regulates miR-132 levels, revealing a dynamic equilibrium between miR-132 and p300. By targeting p300, rather than a transcription factor or signalling protein, miR-132 has a broad role in the regulation of antiviral immunity.


Nucleic Acids Research | 2010

Efficient inhibition of miR-155 function in vivo by peptide nucleic acids

Martin M. Fabani; Cei Abreu-Goodger; Donna Williams; Paul A. Lyons; Adrian Gabriel Torres; Kenneth G. C. Smith; Anton J. Enright; Michael J. Gait; Elena Vigorito

MicroRNAs (miRNAs) play an important role in diverse physiological processes and are potential therapeutic agents. Synthetic oligonucleotides (ONs) of different chemistries have proven successful for blocking miRNA expression. However, their specificity and efficiency have not been fully evaluated. Here, we show that peptide nucleic acids (PNAs) efficiently block a key inducible miRNA expressed in the haematopoietic system, miR-155, in cultured B cells as well as in mice. Remarkably, miR-155 inhibition by PNA in primary B cells was achieved in the absence of any transfection agent. In mice, the high efficiency of the treatment was demonstrated by a strong overlap in global gene expression between B cells isolated from anti-miR-155 PNA-treated and miR-155-deficient mice. Interestingly, PNA also induced additional changes in gene expression. Our analysis provides a useful platform to aid the design of efficient and specific anti-miRNA ONs for in vivo use.


Nucleic acids symposium series (2004) | 2008

PNA-peptide conjugates as intracellular gene control agents.

Gabriela D. Ivanova; Martin M. Fabani; Andrey A. Arzumanov; Rachida Abes; HaiFang Yin; Bernard Lebleu; Matthew J.A. Wood; Michael J. Gait

Serum-stabilized PNA-internalization peptides (Pip) conjugated to PNA complementary to the 705 aberrant beta-globin splice site are able to correct splicing and increase luciferase production in Hela pLuc705 cells with sub microM EC(50) in the absence of a transfection agent. Inhibition of microRNA-122 in liver cells is achieved by treatment with complementary PNA containing just a few attached Lys residues, again without need of a transfection agent.


Journal of Nucleic Acids | 2011

Site-selective artificial ribonucleases: oligonucleotide conjugates containing multiple imidazole residues in the catalytic domain.

Natalia Beloglazova; Martin M. Fabani; Nikolai N. Polushin; Vladimir V. Sil'nikov; Valentin V. Vlassov; Elena V. Bichenkova; Marina A. Zenkova

Design of site-selective artificial ribonucleases (aRNases) is one of the most challenging tasks in RNA targeting. Here, we designed and studied oligonucleotide-based aRNases containing multiple imidazole residues in the catalytic part and systematically varied structure of cleaving constructs. We demonstrated that the ribonuclease activity of the conjugates is strongly affected by the number of imidazole residues in the catalytic part, the length of a linker between the catalytic imidazole groups of the construct and the oligonucleotide, and the type of anchor group, connecting linker structure and the oligonucleotide. Molecular modeling of the most active aRNases showed that preferable orientation(s) of cleaving constructs strongly depend on the structure of the anchor group and length of the linker. The inclusion of deoxyribothymidine anchor group significantly reduced the probability of cleaving groups to locate near the cleavage site, presumably due to a stacking interaction with the neighbouring nucleotide residue. Altogether the obtained results show that dynamics factors play an important role in site-specific RNA cleavage. Remarkably high cleavage activity was displayed by the conjugates with the most flexible and extended cleaving construct, which presumably provides a better opportunity for imidazole residues to be correctly positioned in the vicinity of scissile phosphodiester bond.


Archive | 2008

Chapter 4:Peptide–Peptide Nucleic Acid Conjugates for Modulation of Gene Expression

Martin M. Fabani; Gabriela D. Ivanova; Michael J. Gait

When Zamecnik and Stephenson first proposed synthetic oligodeoxyribonucleotides as reagents to bind to Rous sarcoma virus RNA to inhibit viral replication, they designed an oligonucleotide (ON) to target the initiation site for protein translation in the expectation that it would form an RNA–DNA dup...


RNA | 2007

miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA–peptide conjugates

Martin M. Fabani; Michael J. Gait


Blood Cells Molecules and Diseases | 2007

RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA

John J. Turner; Simon W. Jones; Martin M. Fabani; Gabriela D. Ivanova; Andrey A. Arzumanov; Michael J. Gait


RNA | 2011

MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection.

Adrian Gabriel Torres; Martin M. Fabani; Elena Vigorito; Michael J. Gait


Biochimica et Biophysica Acta | 2006

Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: Chemistry and cell delivery

John J. Turner; Martin M. Fabani; Andrey A. Arzumanov; Gabriela D. Ivanova; Michael J. Gait


Nucleic Acids Research | 2004

Sequence-specific artificial ribonucleases. I. Bis-imidazole-containing oligonucleotide conjugates prepared using precursor-based strategy

Natalia Beloglazova; Martin M. Fabani; Marina A. Zenkova; Elena V. Bichenkova; Nikolai N. Polushin; Vladimir V. Sil'nikov; Kenneth T. Douglas; Valentin V. Vlassov

Collaboration


Dive into the Martin M. Fabani's collaboration.

Top Co-Authors

Avatar

Michael J. Gait

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Gabriela D. Ivanova

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Andrey A. Arzumanov

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

John J. Turner

Laboratory of Molecular Biology

View shared research outputs
Top Co-Authors

Avatar

Marina A. Zenkova

Russian Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge